Quanterix : Up 6% Following Abbott License Agreement, Cannacord Price Target Boost

By Josh Beckerman

Shares of biomarker analysis company Quanterix Corp. were recently up 6% to $37.50 as it entered a non-exclusive license agreement with Abbott Laboratories and Cannacord Genuity raised its price target to $40 from $38.

Quanterix said Monday that the royalty-bearing license grants Abbott access to bead-based technology patents for use with in vitro diagnostic applications. Quanterix will receive an initial license fee.

Write to Josh Beckerman at [e-mail]

(END) Dow Jones Newswires

10-06-20 1424ET